EGFR and central nervous system cancer: Several clinically significant molecular alterations (including mutations in IDH, 1p/19q, MGMT, and EGFR) have been described in gliomas and combined with histology for tumor classification (Eckel-Passow et al., 2015; Hoshide and Jandial, 2016; Louis et al., 2016; Jiang et al., 2020).